DAPK1 and lymphoma: The fixed-effects model showed that the 5-year survival rate was significantly lower in lymphoma patients with DAPK methylation than in patients without methylation (RR = 0.85, 95% CI (0.73, 0.98), P = 0.025) (Fig 2A).